Clinical Efficacy of Leech Therapy (Ta'liq al-'Alaq) in Eczema (Nar Farsi): An Open-Label Single-Arm Clinical Study
Ulla P BS, Aaisha B, Bokhari S, Zabiulla P, Alam MA, Nikhat S (2025) · Alternative Therapies in Health and Medicine · n=20
Studienprofil
- Design
- single-center, open-label, single-arm clinical study of leech therapy for eczema in the Unani medicine tradition (India)
- Stichprobengröße (n)
- 20
- Intervention
- Four sessions of leech therapy with one-week intervals; standardized Ta'liq al-'Alaq (leech therapy) protocol per Unani medicine practice
- Komparator
- Within-subject pre/post comparison using standardized Eczema Area and Severity Index (EASI) - no randomized control arm
- Primärer Endpunkt
- Eczema Area and Severity Index (EASI) score - components for redness, edema, excoriation, lichenification, and total area
- Primäres Ergebnis
- Statistically significant improvement in eczema severity: redness (p=0.0001), edema (p=0.0001), excoriation (p=0.0022), lichenification (p=0.0001); total area involved did not show statistically significant decrease (p=0.24); all 20 patients completed the trial with no dropouts
- Follow-up-Dauer
- 4 weekly sessions (~28 days)
- PMID
- 40293844
Wichtigste Ergebnisse
- First PubMed-indexed Unani medicine clinical trial of leech therapy for eczema (Nar Farsi)
- Significant within-subject improvements in three of four EASI components (redness, edema, excoriation, lichenification)
- Total skin area involvement did not significantly decrease - suggests symptomatic improvement without disease-modifying area reduction
- 100% completion rate (no dropouts) signals patient acceptability of multi-session leech protocol
- Provides hypothesis-generating signal for leech therapy in inflammatory dermatologic conditions
Einschränkungen
- Single-arm design with no randomized control - entire effect could reflect natural fluctuation, placebo, or attention
- Small sample (n=20)
- Open-label evaluation by treating clinicians who knew the intervention
- Single Unani medicine institution - selection bias toward CAM-favorable patient population
- Eczema is a relapsing-remitting condition - 4-week follow-up cannot assess durability
Klinische Implikationen
Ulla 2025 is the only PubMed-indexed Unani-medicine clinical study of leech therapy for eczema and provides exploratory evidence that leech application may improve inflammatory eczema parameters. The single-arm uncontrolled design limits causal inference, and the lack of total-area improvement suggests symptomatic-only effect. For ASH editorial purposes, this study is cited only as preliminary cross-cultural evidence; it does not support routine use in eczema. The trial illustrates the broader Unani medicine application of leech therapy across dermatologic indications - a use case largely absent from the Western evidence base.
Verwandte Studien
Effectiveness of leech therapy in osteoarthritis of the knee: a randomized, controlled trial
Michalsen A, Klotz S, Lüdtke R, Moebus S, Spahn G, Dobos GJ (2003)
Leech therapy for symptomatic treatment of knee osteoarthritis: results and implications of a pilot study
Andereya S, Stanzel S, Maus U, Mueller-Rath R, Mumme T, Miltner O (2006)
Comparison of modern leech therapy with intra-articular hyaluronic acid injections for symptomatic relief of knee osteoarthritis
Andereya S, Stanzel S, Maus U, Mueller-Rath R, Mumme T, Miltner O, Andereya S (2008)
A systematic review and meta-analysis of medical leech therapy for osteoarthritis of the knee
Lauche R, Cramer H, Langhorst J, Dobos G (2014)